Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
November 10, 2022 01:01 ET
|
Celyad Oncology SA
Company continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discoveryClinical updates expected by end of year for the Phase 1...
Lavras Gold’s Third Quarter Marked by Discovery
November 07, 2022 16:45 ET
|
Lavras Gold Corp
The news release should be read in conjunction with our unaudited interim consolidated financial statements and management’s discussion and analysis for the period ended September 30, 2022. Both are...
Ashton Woods USA L.L.C. Announces Quarterly Results Conference Call
September 30, 2022 09:00 ET
|
Ashton Woods Homes
Alpharetta, Ga., Sept. 30, 2022 (GLOBE NEWSWIRE) -- ASHTON WOODS USA L.L.C. ANNOUNCES QUARTERLY RESULTS CONFERENCE CALL Ashton Woods USA L.L.C. (the “Company”) announced today that the...
Connexa Sports Technologies Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
September 26, 2022 08:00 ET
|
Connexa Sports Technologies Inc.
Baltimore, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Connexa Sports Technologies Inc. (NASDAQ: CNXA) (www.connexasports.com) (the “Company”) announced that it had received a letter from The Nasdaq Stock...
FirstBank Closes Out Second Quarter with Sustained Growth and Top Workplace Ranking
August 15, 2022 10:15 ET
|
FirstBank
LAKEWOOD, Colo., Aug. 15, 2022 (GLOBE NEWSWIRE) -- FirstBank, one of the nation’s largest privately held banks with a focus on “banking for good,” announced continued growth in assets, deposits and...
Immatics veröffentlicht Ergebnisse des zweiten Quartals 2022 sowie ein Update zur Geschäftsentwicklung
August 09, 2022 07:00 ET
|
Immatics N.V.
Patientenrekrutierung in allen drei Phase-1b-Studienkohorten mit ACTengine® IMA203 TCR-T-Zelltherapiekandidaten (Zielstruktur: PRAME) gestartet: IMA203 Monotherapie mit vorläufiger, empfohlener...
Immatics Announces Second Quarter 2022 Financial Results and Business Update
August 09, 2022 07:00 ET
|
https://immatics.com/
ACTengine® TCR-T cell therapy targeting PRAME is enrolling patients in all three Phase 1b cohorts: IMA203 monotherapy at provisional recommended Phase 2 dose (RP2D) (Cohort A), IMA203/nivolumab...
CAPSTONE INFRASTRUCTURE CORPORATION REPORTS SECOND QUARTER RESULTS AND DECLARES A QUARTERLY DIVIDEND
August 08, 2022 16:40 ET
|
Capstone Infrastructure Corporation
Toronto, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Capstone Infrastructure Corporation (TSX: CSE.PR.A) (the "Corporation" or "Capstone") today announced and filed its financial results for the second...
Immatics veröffentlicht Ergebnisse des ersten Quartals 2022 sowie ein Update zur Geschäftsentwicklung
June 02, 2022 07:05 ET
|
Immatics N.V.
ACTengine® IMA203: Erste Patienten mit empfohlener Zieldosis in Phase-1b-Kohorte A mit IMA203-Monotherapie sowie Kohorte B mit IMA203 und Checkpoint-Inhibitor behandelt; Studienzulassung (IND...
Immatics Announces First Quarter 2022 Financial Results and Business Update
June 02, 2022 07:05 ET
|
https://immatics.com/
ACTengine® IMA203: First patients treated at RP2D in Phase 1b cohort A with IMA203 monotherapy as well as Phase 1b cohort B with IMA203/checkpoint inhibitor combination. IND for Phase 1b cohort C with...